PMID- 25015778
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 4
DP  - 2015 Apr
TI  - Update on the molecular pathogenesis and targeted approaches of mantle cell 
      lymphoma: summary of the 12th annual conference of the European Mantle Cell 
      Lymphoma Network.
PG  - 866-76
LID - 10.3109/10428194.2014.940584 [doi]
AB  - Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is 
      characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in 
      constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost 
      all cases. Clinically, MCL shows an aggressive clinical course with a continuous 
      relapse pattern and a median survival of only 3-5 years. However, recently a 
      subset of 15% long-term survivors has been identified with a rather indolent 
      clinical course. Targeted strategies include the proteasome inhibitors, immune 
      modulatory drugs (IMiDs), mammalian target of rapamycin (mTOR) inhibitors and 
      especially inhibitors of the B-cell receptor pathway. Our recent annual 
      conference focused on the molecular pathogenesis of the disease and how these 
      underlying molecular alterations may guide the selection and integration of 
      innovative approaches for therapy. This review of the meeting covers in 
      particular the identification of indolent cases, and deals with the role of the 
      B-cell receptor pathway in MCL, as well as the detection of minimal residual 
      disease and implementation of molecular approaches in current clinical trials.
FAU - Dreyling, Martin
AU  - Dreyling M
AD  - Department of Medicine III, University Hospital/LMU Munich , Germany.
FAU - Amador, Virginia
AU  - Amador V
FAU - Callanan, Mary
AU  - Callanan M
FAU - Jerkeman, Mats
AU  - Jerkeman M
FAU - Le Gouill, Steven
AU  - Le Gouill S
FAU - Pott, Christiane
AU  - Pott C
FAU - Rule, Simon
AU  - Rule S
FAU - Zaja, Francesco
AU  - Zaja F
CN  - European Mantle Cell Lymphoma Network
LA  - eng
PT  - Congress
DEP - 20140820
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Chromosomes, Human, Pair 11/genetics
MH  - Chromosomes, Human, Pair 14/genetics
MH  - Humans
MH  - Lymphoma, Mantle-Cell/*genetics/*therapy
MH  - Molecular Targeted Therapy/*methods/trends
MH  - Neoplasm, Residual/diagnosis/genetics
MH  - Stem Cell Transplantation/*methods
MH  - Survival Analysis
MH  - Translocation, Genetic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Mantle cell lymphoma
OT  - chemotherapy
OT  - minimal residual disease
OT  - molecular pathogenesis
OT  - targeted therapy
EDAT- 2014/07/13 06:00
MHDA- 2016/04/05 06:00
CRDT- 2014/07/13 06:00
PHST- 2014/07/13 06:00 [entrez]
PHST- 2014/07/13 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.3109/10428194.2014.940584 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 Apr;56(4):866-76. doi: 10.3109/10428194.2014.940584. Epub 
      2014 Aug 20.